[
    [
        {
            "time": "2018-03-15",
            "original_text": "Noteworthy ETF Inflows: VTV, USB, LLY, MS",
            "features": {
                "keywords": [
                    "ETF",
                    "Inflows",
                    "VTV",
                    "USB",
                    "LLY",
                    "MS"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Noteworthy ETF Inflows: VTV, USB, LLY, MS",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-04-10",
            "original_text": "Pharma Stock Roundup: LLY's Cyramza Shines in Cancer Study, PFE & AZN in Focus",
            "features": {
                "keywords": [
                    "Pharma",
                    "Stock",
                    "LLY",
                    "Cyramza",
                    "Cancer",
                    "Study",
                    "PFE",
                    "AZN"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pharma Stock Roundup: LLY's Cyramza Shines in Cancer Study, PFE & AZN in Focus",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-04-12",
            "original_text": "Pharma Stock Roundup: LLY's Cyramza Shines in Cancer Study, PFE & AZN in Focus",
            "features": {
                "keywords": [
                    "Pharma",
                    "Stock",
                    "LLY",
                    "Cyramza",
                    "Cancer",
                    "Study",
                    "PFE",
                    "AZN"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pharma Stock Roundup: LLY's Cyramza Shines in Cancer Study, PFE & AZN in Focus",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-05-01",
            "original_text": "Wired News – Eli Lilly's Phase-3 REACH-2 Study of CYRAMZA(R) Met its Primary Endpoint of Overall Survival",
            "features": {
                "keywords": [
                    "Wired",
                    "News",
                    "Eli",
                    "Lilly",
                    "Phase-3",
                    "REACH-2",
                    "Study",
                    "CYRAMZA(R)",
                    "Primary",
                    "Endpoint",
                    "Overall",
                    "Survival"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Wired News – Eli Lilly's Phase-3 REACH-2 Study of CYRAMZA(R) Met its Primary Endpoint of Overall Survival",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]